FDA regulators issued a formal warning letter to ConMed (NSDQ:CNMD) citing numerous violations observed during an inspection of the company’s Colorado manufacturing facility.
ConMed Corp.
ConMed gains on Q4, 2013 earnings, sales beats
ConMed responds to activist investor
ConMed battles ‘activist investor’ amid harsh quarter, lowered forecast
Corrected November 11 2013, at 2:45 p.m.
Listen to ConMed’s Q3 2014 earnings call
ConMed closes tender offer for Viking Systems | Wall Street Beat
ConMed (NSDQ:CNMD) said it’s closed its 27¢-per-share tender offer for Viking Systems (OTC:VKNG), leaving it with about 84% of shares in the medical imaging maker.
ConMed lays out $23M for Viking Systems
Zimmer slides on Q1 results | Earnings Roundup
GE, Masimo ink OEM deal | Wall Street Beat
Masimo meets The Street, shares rise | Earnings Roundup
Masimo (NSDQ:MASI) met Wall Street’s forecast for its full-year and 4th-quarter earnings, giving its shares a 2% bump yesterday and sending them another 3% higher today.
The Irvine, Calif.-based patient monitoring systems maker reported profits of $$13.8 million, or 23 cents per share, on sales of $112.3 million for the 3 months ended Dec. 31, 2011, for a top-line increase of 6.4% but a bottom-line decline of 14.2%, compared with Q4 2010.
Mela Sciences prepares to launch MelaFind with new manufacturing deal | Deals Roundup
Mela Sciences (NSDQ:MELA) announced an expanded 3-year manufacturing contract with long-time supplier Askion GmbH for production of the MelaFind devices.
MelaFind, the company’s flagship product, is a handheld, non-invasive melanoma detection and identification system designed to help a physician decide whether or not to biopsy a suspect patch of skin.